ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00240877
Recruitment Status : Completed
First Posted : October 18, 2005
Last Update Posted : November 20, 2008
Sponsor:
Information provided by:
MedImmune LLC

Brief Summary:
To assess the safety of a vaccine in healthy adults prior to the release of the trivalent vaccine (FluMist).

Condition or disease Intervention/treatment Phase
Influenza Biological: AV024 Other: Placebo Phase 3

Detailed Description:
The primary study objective is to assess the safety of a monovalent vaccine of a new 6:2 reassortant in healthy adults prior to the release of the trivalent vaccine (FluMist). Safety will be demonstrated by similar fever rates (oral temperature ≥101°F) in vaccine and placebo recipients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)
Study Start Date : August 2002
Actual Primary Completion Date : August 2003
Actual Study Completion Date : April 2004

Arm Intervention/treatment
Experimental: 1
Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
Biological: AV024
0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
Placebo Comparator: 2
Placebo
Other: Placebo
Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).



Primary Outcome Measures :
  1. - The primary endpoint of this study is fever defined as oral temperature ≥101°F [ Time Frame: Days 0-7 ]

Secondary Outcome Measures :
  1. All other reported reactogenicity events and other adverse events. [ Time Frame: After 7 days after vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-64 years of age (not yet reached their 65th birthday);
  • In good health;
  • Available by telephone;
  • Ability to understand and comply with the requirements of the protocol; and
  • Signed informed consent.

Exclusion Criteria:

  • Any condition, other than age, for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical follow-up or hospitalization during the proceeding year;
  • Acute febrile (>100.0°F oral) illness or clinically significant respiratory illness within the 14 days prior to enrollment;
  • Hypersensitivity to egg or egg protein;
  • Signs or symptoms of any immunosuppressive or immune deficiency disease, including HIV infection, or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household;
  • Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study; and
  • Any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240877


Locations
United States, Florida
SFBC International Inc
Miami, Florida, United States, 33181
Sponsors and Collaborators
MedImmune LLC
Investigators
Study Director: Robert Walker, MD MedImmune LLC

Responsible Party: Robert Walker, M.D., MedImmune Inc.
ClinicalTrials.gov Identifier: NCT00240877     History of Changes
Other Study ID Numbers: AV024
First Posted: October 18, 2005    Key Record Dates
Last Update Posted: November 20, 2008
Last Verified: November 2008

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs